Immatics

This year at Immatics, our staff motto is #MoveIt and that’s exactly what our team did at the 8th annual Hess Houston Corporate 5K! More than 50 of our colleagues came together to Memorial Park Conservancy to run/walk at Houston’s “Largest Office Party” to promote corporate wellness and team building. After crossing the finish line, our team celebrated at the Immatics tent with healthy snacks, refreshing drinks, live entertainment and more! It was a fun challenge and an excellent opportunity to demonstrate the determination we embody at Immatics in our daily mission of improving the lives of cancer patients. #HESS5K #GetFitHouston #TeamBuilding #EmployeeWellness #memorialpark #runhouston #CorporateWellness

Our Director Clinical Development, Olga Veremchuk, had the pleasure of attending the 65th Congress of the German Society for Gynecology and Obstetrics (DGGG) in Berlin. The DGGG Congress focuses on advancements in gynecology, obstetrics and gynecological cancers, offering a great opportunity for Immatics to engage with the latest clinical research, therapies and treatment strategies aimed at improving cancer care for women. Here are some takeaways from the event: 💡Future treatments for endometrial cancer will focus on using molecular subgroups to better predict outcomes and personalize therapies 💡Newer antibody-drug conjugates (ADCs) are showing positive results in gynecological cancers 💡Next generation immuno-oncology trials, including bispecific antibodies, are now underway Our Immatics team is excited to apply these insights as we continue to advance our TCR-based immunotherapies. #DGGG2024 #Gynecology #Obstetrics #WomensHealth #Innovation #Berlin #Collaboration

In case you missed it: Last week, we announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in metastatic melanoma patients. We also provided an update on SUPRAME, the upcoming registration-enabling Phase 3 trial to evaluate IMA203 in cutaneous melanoma patients. Read the full announcement here: https://lnkd.in/eF56m5ni #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews

Today we announced a $150 million public offering. As a biotechnology company with several TCR-based cell therapy and bispecific product candidates moving through clinical development, this financing will further support us in the advancement of our targeted immunotherapies for patients with solid tumors. Read the full press release here: https://lnkd.in/dF8TD_2i #financing #biotech #oncology #cancer #corporatenews #financialnews #healthcare

Today we announced updated Phase 1b clinical data on ACTengine® IMA203 in metastatic melanoma patients and provided an update on the upcoming Phase 3 trial, “SUPRAME.” To read the full announcement, click here: https://lnkd.in/eF56m5ni We will also host a conference call and webcast today, October 10th at 9:00 am EDT / 3:00 pm CEST. The link to the webcast is available in the comments section below and in the press release. #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews

Today we announced upcoming presentations at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. We are thrilled that the conference will take place in Houston, Texas, home to one of Immatics' three locations. For details, read the full press release here: https://lnkd.in/eaT7H3rb #cancer #immunotherapy #SITC #immunooncology #immunology

A day of sun, family and fun! As part of the recent move to our new facility in Stafford, Texas, we invited our colleagues and their families to celebrate all our teams and their hard work with a Family Fun Day event. This was a morning full of fun, food, games and entertainment, featuring a dunk tank with special participation from our COO Steffen Walter, face painting, science booths, delicious local food and more. Check out a few snapshots from the event! Photo credit: ProReal Media #TeamCelebration #FamilyEvent #CompanyCulture #EmployeeEngagment #FamilyFunDay #TeamBuilding #Together

Last week, our Senior Director Clinical Development, Oliver Ebert, Director Clinical Sciences, Sabine Kastner, Associate Director Clinical Development, Irene Heimbeck and Senior Manager Clinical Development, Karina Schuck, attended the ADO Kongress in Würzburg, Germany, an annual event that brings together experts in dermatologic oncology to discuss the most current advancements in skin cancer research. Our ACTengine® IMA203 clinical data as of April 25, 2024, was featured in an e-poster at the event. We are proud of our team’s contributions and look forward to continuing to shape a healthier future for cancer patients. #ADO2024 #ADOKongress #melanom #onkologie #PowertothePatients #skincancer #oncology

This month, the Immatics team traveled to Boston for the 9th Annual CAR-TCR Summit Series, where insightful discussions on progress in the field of cell therapy took center stage. Our team members, Mamta Kalra, Delfi Krishna and Ali Mohamed, PhD advanced the conversation and showcased Immatics’ innovative work through presentations and panel sessions. Key takeaways from CAR-TCR Summit 2024 include: 👉There is a strong focus on shortening manufacturing processes and QC release times for autologous cell therapy to maximize patient access on a global scale and reduce cost of goods and vein-to-vein time. 👉New off-the-shelf technological solutions are being developed to advance cell therapy manufacturing, including new equipment and automation options. 👉The application of cell therapy is expanding beyond oncology to include autoimmune diseases, with promising progress made in the in vivo engineering of T cells via viral and mRNA platforms. We are proud of the contributions our team made and look forward to continuing our journey of innovation in cell therapy, with the ultimate goal of improving the lives of cancer patients. #CAR_TCR2024 #CellTherapy #Innovation #SummitRecap #CARTCR #ScienceResearch #cancer #oncology

“Let’s team up for cancer research because if cancer doesn’t care about distance, neither do we.” – World Cancer Research Day Organization. 🌍 September 24th is World Cancer Research Day and serves as a reminder of the importance of global collaboration in the fight against cancer. 🏢 At Immatics, our commitment to developing innovative immunotherapies for solid tumors spans across our offices in Tübingen, Munich and Houston. We also engage with experts worldwide, integrating diverse perspectives and expertise to advance our mission of improving outcomes for cancer patients. ⚕️Visit the World Cancer Day Research website to discover the extensive international network driving innovation and new therapies in cancer research: https://lnkd.in/d3sCkBs #WorldCancerResearchDay #CancerResearch #Oncology #CancerTreatment #CARTCellTherapies #CancerAwarenes #CancerTreatment #WCRD